Laurent Peyrin-Biroulet to Time Factors
This is a "connection" page, showing publications Laurent Peyrin-Biroulet has written about Time Factors.
Connection Strength
0.101
-
Adherence to infliximab therapy in inflammatory bowel disease patients in a real-life setting. J Dig Dis. 2017 Oct; 18(10):566-573.
Score: 0.033
-
Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. Gastroenterology. 2019 10; 157(4):1032-1043.e1.
Score: 0.009
-
PF-00547659 for the treatment of Crohn's disease and ulcerative colitis. Expert Opin Investig Drugs. 2018 Jul; 27(7):623-629.
Score: 0.009
-
Prolonged azathioprine treatment reduces the need for surgery in early Crohn's disease. J Gastroenterol Hepatol. 2018 Mar; 33(3):664-670.
Score: 0.009
-
Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience. Aliment Pharmacol Ther. 2018 03; 47(5):588-595.
Score: 0.008
-
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. Gastroenterology. 2018 04; 154(5):1343-1351.e1.
Score: 0.008
-
Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis. Aliment Pharmacol Ther. 2018 01; 47(2):219-228.
Score: 0.008
-
Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease. Dig Liver Dis. 2017 Oct; 49(10):1086-1091.
Score: 0.008
-
Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort. Gut. 2017 04; 66(4):588-596.
Score: 0.007